SEP 1 6 2002 3

Sheet 1 of **ATTORNEY** Form PTO-1449 IRSY. 7.801 1300-1-008 DOCKET U.S. Department of Commerce NO. Patent and Trademark Office SERIAL NO. 09/831,534 **APPLICANT** Bryan John Smith LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT **FILING** May 10, 2001 (Use several sheets if necessary) DATE GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	 DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
MD	AA	WO 92/22583	12/23/92	PCT			
140	AB	WO 97/34631	09/25/97	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

my) AC	K.A. Barr, Pharmaceutical Engineering, Protocol for Efficient Secretion of HSA Developed from Pichia pastoris, 12:48-51, March/April 1992.		
w	AD	L. Bartalena, Clinics in Laboratory Medicine, Thyroid Hormone Transport Proteins, 13:583-598, September 1993.		
us	AE	M. Better, International Genetic Engineering, Inc., Escherichia coli Secretion of an Active Chimeric Antibody Fragment, 240:1041-043, May 1988.		
MO	AF	F. Bree, Clinical Pharmacokinetics, Pharmacokinetcs of Intravenously Administered 125I-Labelled Human α1-Acid Glycoprotein,11:336-342, 1986.		
40	AG	A.P. Chapman, Nature Biotechnology, therapeutic antibody fragments with prolonged in vivo half-lives, 17:780-783, August 1999.		
EXAMINER DATE CONSIDERED: 16/20/15				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEP 1 6 2002

Sheet 2 of 3 ATTORNEY, DOCKET 1300-1-008 IRSY. 7.801 Form PTO:1449 NO. U.S. Department of Commerce Patent and Trademark Office SERIAL NO. 09/831,534 Bryan John Smith **APPLICANT** LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT May 10, 2001 FILING DATE (Use several sheets if necessary) 1646 GROUP

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		OTHER PRIOR ACT (Including Author, Title, Date, Fertillett Fages, Ltc.)	
nis)	АН	D.J. Chiswell, Tibtech, Phage antibodies: will new 'coliclonal' antibodies replace monoclonal antibodies?, 10:80-84, March 1992.	
NU	A!	J.M. Cregg, Bio/Technology, Recent advances in the Expression of foreign Genes in Pichia pastoris, 11:905-910, August 1993.	
5	AJ	R. Fleer, Bio/Technology, Stable Multicopy Vectors For High-Level Secretion of Recombinant Human Serum Albumin by Kluyveromyces Yeasts, 9:968-975, October 1991.	
Nas)ak	D. Gitlin, Journal of Clinical Investigation, The Selectivity of the Human Placenta in the Transfer of Plasma Proteins from Mother to Fetus, 10:1938-1951, 1964.	
MC	AL	A.H. Horwitz, Proceedings of the National Academy of Sciences of the United States of America, Secretion of Functional Antibody and Fab Fragment from Yeast Cells, 85:8678-8682, 1988.	
200	АМ	D.R. Hurwitz, Transgenic Research, Specific combinations of human serum albumin introns direct high level expression of albumin in transfected COS cells and in the milk of transgenic mice, 3:365-375, 1994.	
NO	AN	J.K. Kim, Eur. J. Immunol, Localization of the site of the murine IgG1 molecule that is involved in binding to the murin intestinal Fc receptor, 24:2429-2434, 1994.	
M	AO	W. Kramer, Nucleic Acids Research, The gapped duplex DNA approach to oligonucleotide-directed mutation construction, 12:9441-9457, 1984.	
NO	AP	D. Kraus, Behring Inst. Mitt, Determination of Affinities of Murine and Chimeric Anti-χ/β- T Cell Receptor antibodies by Flow Cytomertry, 87:56-67, 1990	
va	AQ)	C. Medesan, The American Association of Immunologists, Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1 ¹ , 158:2211-2217, 1997.	
KY	AR	M. Nose, Proceedings of the National Academy of Sciences of the United States of America, 80:6632-6636, 1983 Biscopy Sign. A Carbohydrake Charis in Minoclarel Hi	s brdrej
150	AS	A. A. Ogunjimi, Biotechnology, High-level secretory expression of immunologically active intact antibody from the yeast Pichia pastoris, 21:561-567, 1999.	
M	(A)	T. Peters, Advances in Protein Chemistry, Serum Albumin, 37:161-245, 1985	
mo	AU	F. Sanger, Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977.	
NSP	AV	D. Sleep, Bio/Technology, Saccharomyces Cerevisiae Strains that Overexpress Heterologous Proteins, 9:183-187, February 1991.	
W	AW	K. Sreekrishna, Gene, Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris, 190:55-62, 1997.	

M. R

opolos

SEP 1 6 2007

ATTORNEY. DOCKET 1300-1-008 IRSY. 7.801 Form PTO:1449 U.S. Department of Commerce Patent and Trademark Office SERIAL NO. 09/831,534 **APPLICANT** Bryan John Smi LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT FILING DATE May 10, 2001 (Use several sheets if necessary) GROUP

Sheet 3 of 3

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

NU) ^{AX}	S. Syed, Blood, Potent Antithrombin Activity and Delayed Clearance from the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin, 89:3243-3252, May 1997			
~~\/\(\lambda\)	AY	M.H. Tao, Journal of Immunology, Studies of Aglycosylated Chimeric Mouse-Human IgG Role of Carbohydrate in the Structure and Effector functions Mediated by the Human IgG Constant Region, 143:2595-2601, October 1989.			
MD	AZ	T.A. Waldmann, Progr. Allergy, Metabolism of Immunooglobulins, 13:1-110, 1969.			
4	ва	E.J. Wawrzynczak, Molecular Immunology, Blood Clearance in the Rat of a Recombinant Mouse Monoclonal Antibody Lacking the N-Linked Oligosaccharide Side Chains of the C _H 2 Domains, 29:213-220, 1992			
40	ВВ	N. Yukawa, Journal of Immunoassay, Bispecific Rabbit Fab ⁹ -Bovine Serum Albumin Conjugate used in Hemagglutination Immunoassay for β-Microseminoprotein, 18:215-233, 1997.			
wo	вс	P. Yeh, Proceedings of the National Academy of Sciences of the United States of America, Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum albumin-CD4 Genetic Conjugate, 89;1904-1908, 1992.			
EXAMINER: DATE CONSIDERED: (0/20/0)					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.